Epithelial–mesenchymal transition in cancer development and its clinical significance

The epithelial–mesenchymal transition (EMT) plays a critical role in embryonic development. EMT is also involved in cancer progression and metastasis and it is probable that a common molecular mechanism is shared by these processes. Cancer cells undergoing EMT can acquire invasive properties and enter the surrounding stroma, resulting in the creation of a favorable microenvironment for cancer progression and metastasis. Furthermore, the acquisition of EMT features has been associated with chemoresistance which could give rise to recurrence and metastasis after standard chemotherapeutic treatment. Thus, EMT could be closely involved in carcinogenesis, invasion, metastasis, recurrence, and chemoresistance. Research into EMT and its role in cancer pathogenesis has progressed rapidly and it is now hypothesized that novel concepts such as cancer stem cells and microRNA could be involved in EMT. However, the involvement of EMT varies greatly among cancer types, and much remains to be learned. In this review, we present recent findings regarding the involvement of EMT in cancer progression and metastasis and provide a perspective from clinical and translational viewpoints. (Cancer Sci 2009)

[1]  Jeremy J. W. Chen,et al.  Transcription Repressor Slug Promotes Carcinoma Invasion and Predicts Outcome of Patients with Lung Adenocarcinoma , 2005, Clinical Cancer Research.

[2]  M. Tsuneyoshi,et al.  Vimentin‐positive adenocarcinomas of the stomach: co‐expression of vimentin and cytokeratin , 1996, Histopathology.

[3]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[4]  C. Iacobuzio-Donahue,et al.  Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. , 2007, Cancer research.

[5]  A S Leong,et al.  Vimentin—a new prognostic parameter in breast carcinoma? , 1989, The Journal of pathology.

[6]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[7]  M. Rubin,et al.  E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.

[8]  G. Prindull.  Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? , 2005, Experimental hematology.

[9]  A. Seifalian,et al.  Role of stem cells in cancer therapy and cancer stem cells: a review , 2007, Cancer Cell International.

[10]  D. Liu,et al.  Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients , 2003, British Journal of Cancer.

[11]  D. Radisky,et al.  Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT? , 2007, Journal of cellular biochemistry.

[12]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[13]  Kenneth K Wang,et al.  Esophageal Squamous Cell Carcinoma , 2015 .

[14]  H. Kajiyama,et al.  Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients , 2007, British Journal of Cancer.

[15]  H. Kajiyama,et al.  Twist expression in patients with cervical cancer is associated with poor disease outcome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[17]  J. Zavadil,et al.  TGF-beta and epithelial-to-mesenchymal transitions. , 2005, Oncogene.

[18]  Sung-Liang Yu,et al.  Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. , 2009, American journal of respiratory and critical care medicine.

[19]  M. Monden,et al.  Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer , 2007, British Journal of Cancer.

[20]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[21]  K. Miyazaki,et al.  Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma , 2005, British Journal of Cancer.

[22]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[24]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[25]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[26]  Y. Atomi,et al.  Possible contribution of CD44 variant 6 and nuclear β‐catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma , 2001 .

[27]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[28]  P. Bunn,et al.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma , 2007, Molecular Cancer Therapeutics.

[29]  K. Münstedt,et al.  Association between fibronectin expression and prognosis in ovarian carcinoma. , 2003, Anticancer research.

[30]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[31]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[32]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[33]  B. Boyer,et al.  Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.

[34]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[35]  G. Siegal,et al.  Silencing of Transforming Growth Factor-β1 In situ by RNA Interference for Breast Cancer: Implications for Proliferation and Migration In vitro and Metastasis In vivo , 2008, Clinical Cancer Research.

[36]  G. Watkins,et al.  Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast Cancer , 2005, Annals of Surgical Oncology.

[37]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[38]  M. Yasutomi,et al.  Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis , 1995, Cancer.

[39]  M. Mullendore,et al.  An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer , 2008, Molecular Cancer Therapeutics.

[40]  S. Natsugoe,et al.  Slug Expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  S. Natsugoe,et al.  Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. , 2007, Oncology reports.

[42]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[43]  P. Speight,et al.  Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells , 2004, British Journal of Cancer.

[44]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[45]  L. Liotta,et al.  General mechanisms of metastasis , 1997, Cancer.

[46]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[47]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. G. Herreros,et al.  The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells , 2000, Nature Cell Biology.

[49]  Domenico Coppola,et al.  MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.

[50]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[51]  Woonyoung Choi,et al.  miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy , 2009, Clinical Cancer Research.

[52]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[53]  F. Portillo,et al.  Transcriptional regulation of cadherins during development and carcinogenesis. , 2004, The International journal of developmental biology.

[54]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[55]  A. Pintzas,et al.  Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. , 2009, Biochimica et biophysica acta.

[56]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[57]  E. Fredlund,et al.  Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. , 2005, Seminars in cell & developmental biology.

[58]  E. Hay,et al.  Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells , 1982, The Journal of cell biology.

[59]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[60]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[61]  K. Garber.  Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. , 2008, Journal of the National Cancer Institute.

[62]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[63]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[64]  D. Wion,et al.  Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. , 2007, Cancer letters.

[65]  G. Feldmann,et al.  Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival , 2008, British Journal of Cancer.

[66]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[67]  J. Cerhan,et al.  Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  G. Kristiansen,et al.  Claudin-1 Protein Expression is a Prognostic Marker of Patient Survival in Renal Cell Carcinomas , 2008, Clinical Cancer Research.

[69]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[70]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[71]  H. Wallerand,et al.  N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors , 2006, Clinical Cancer Research.

[72]  Thomas Kirchner,et al.  Migrating cancer stem cells — an integrated concept of malignant tumour progression , 2005, Nature Reviews Cancer.

[73]  K. Chu,et al.  Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Takaaki Masuda,et al.  N-Cadherin Is Regulated by Activin A and Associated with Tumor Aggressiveness in Esophageal Carcinoma , 2004, Clinical Cancer Research.

[75]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[76]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[77]  H. Kajiyama,et al.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. , 2007, International journal of oncology.

[78]  T. Dønnem,et al.  The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer , 2008, British Journal of Cancer.

[79]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[80]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[81]  G. Berx,et al.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.

[82]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[83]  E. Kubista,et al.  Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.

[84]  D. Newgreen,et al.  Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors , 2007, Breast Cancer Research.

[85]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[86]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[87]  M. Bracken,et al.  E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis , 2006, Breast Cancer Research and Treatment.

[88]  T. Fujii,et al.  Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. , 2008, Cancer research.

[89]  E. Hay,et al.  The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[90]  Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients , 2006, British Journal of Cancer.

[91]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[92]  L. Turkeri,et al.  Analytical and Clinical Evaluation of a New Urinary Tumor Marker: Bladder Tumor Fibronectin in Diagnosis and Follow-up of Bladder Cancer , 2003, Clinical chemistry and laboratory medicine.

[93]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[94]  K. Mimori,et al.  Cancer stem cells and chemoradiation resistance , 2008, Cancer science.

[95]  Benjamin A. Onwuegbusi,et al.  In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. , 2006, Cancer research.

[96]  A. Cano,et al.  Snail silencing effectively suppresses tumour growth and invasiveness , 2007, Oncogene.

[97]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[98]  H. Cheung,et al.  Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells , 2004, Oncogene.

[99]  Zhiwei Wang,et al.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. , 2009, Cancer research.

[100]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  R. Poulsom,et al.  E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. , 1993, The American journal of pathology.

[102]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[103]  R. Knuechel,et al.  Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Ben Davidson,et al.  Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. , 2008, Human pathology.

[105]  R. Poulsom,et al.  Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. , 1995, British Journal of Cancer.

[106]  I. Han,et al.  Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. , 2007, European journal of cancer.